Challenges in Drug Surveillance: Strengthening the Analysis of New Psychoactive Substances by Harmonizing Drug Checking Services in Proficiency Testing

Author:

Balcaen Margot1ORCID,Ventura Mireia2,Gil Cristina2ORCID,Luf Anton3ORCID,Martins Daniel4ORCID,Cunha Mar4,Tögel-Lins Karsten5,Wolf Danny5,Blanckaert Peter1,Deconinck Eric6ORCID

Affiliation:

1. Unit Illicit Drugs, Lifestyle and Chronic Diseases, Scientific Direction Epidemiology, Sciensano, 1050 Brussels, Belgium

2. Energy Control, Associació Benestar i Desenvolupament, 08041 Barcelona, Spain

3. Clinical Department of Laboratory Medicine, Medical University of Vienna, Waehringer Guertel 18–20, 1090 Vienna, Austria

4. Kosmicare, 1170-283 Lisbon, Portugal

5. Legal-high-Inhaltsstoffe, 60439 Frankfurt, Germany

6. Service Medicines and Health Products, Scientific Direction Physical and Chemical Health Risks, Sciensano, J. Wytsmanstraat 14, 1050 Brussels, Belgium

Abstract

Background: Drug checking is a proven harm reduction strategy and provides real-time information on the market of new psychoactive substances (NPS). It combines chemical analysis of samples with direct engagement with people who use drugs (PWUD), giving the ability to increase preparedness and responsiveness towards NPS. Next to that, it supports rapid identification of potential unwitting consumption. However, NPS cause a toxicological battle for the researchers, as factors such as the unpredictability and quick shift of the market complicate the detection. Methods: To evaluate challenges posed towards drug checking services, proficiency testing was set up to evaluate existing analytical techniques and investigate the capability to correctly identify circulating NPS. Twenty blind substances, covering the most common categories of substances, were analyzed according to the existing protocols of the existing drug checking services, including several analytical methods such as gas chromatography–mass spectrometry (GC-MS) and liquid chromatography with diode array detector (LC-DAD). Results: The proficiency test scores range from 80 to 97.5% accuracy. The most common issues and errors are mainly unidentified compounds, presumably due to no up-to-date libraries, and/ or confusion between structural isomers, such as 3- and 4-chloroethcathinone, or structural analogs, such as MIPLA (N-methyl-N-isopropyl lysergamide) and LSD (D-lysergic acid diethylamide). Conclusions: The participating drug checking services have access to adequate analytical tools to provide feedback to drug users and provide up-to-date information on NPS.

Funder

European Justice Programme

Field of Drugs Policy

Publisher

MDPI AG

Subject

Health, Toxicology and Mutagenesis,Public Health, Environmental and Occupational Health

Reference44 articles.

1. European Monitoring Centre for Drug and Drug Addiction (2019). EMCDDA Operating Guidelines for the European Union Early Warning System on New Psychoactive Substances, Publications Office of the European Union.

2. European Monitoring Centre for Drug and Drug Addiction (2022). European Drug Report 2022: Trends and Developments, Publications Office of the European Union. Available online: https://www.emcdda.europa.eu/publications/edr/trends-developments/2022_en.

3. New psychoactive substances: Current health-related practices and challenges in responding to use and harms in Europe;Pirona;Int. J. Drug Policy,2017

4. Patil, V., Tewari, A., and Rao, R. (2022, October 27). New Psychoactive Substances: Issues and Challenges. Available online: https://www.jmhhb.org/article.asp?issn=0971-8990.

5. New psychoactive substances: Challenges for drug surveillance, control, and public health responses;Peacock;Lancet,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3